D.B. Root & Company LLC Acquires 200 Shares of Thermo Fisher Scientific Inc. $TMO

D.B. Root & Company LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 21.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,120 shares of the medical research company’s stock after buying an additional 200 shares during the period. D.B. Root & Company LLC’s holdings in Thermo Fisher Scientific were worth $557,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Thermo Fisher Scientific by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company’s stock valued at $16,659,627,000 after purchasing an additional 230,382 shares during the period. Northern Trust Corp boosted its holdings in Thermo Fisher Scientific by 13.2% in the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company’s stock valued at $2,034,107,000 after purchasing an additional 455,004 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Thermo Fisher Scientific by 4.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company’s stock valued at $1,455,774,000 after purchasing an additional 115,463 shares during the period. Pictet Asset Management Holding SA boosted its holdings in Thermo Fisher Scientific by 7.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company’s stock valued at $1,432,816,000 after purchasing an additional 193,378 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Thermo Fisher Scientific by 11.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,420,949 shares of the medical research company’s stock valued at $1,259,450,000 after purchasing an additional 257,462 shares during the period. 89.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on TMO shares. UBS Group raised their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research report on Thursday, July 24th. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 10th. Argus lowered their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a research report on Tuesday, April 29th. Barclays lifted their target price on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 24th. Finally, Wells Fargo & Company decreased their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a research report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $593.00.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $483.4280 on Friday. The firm has a market cap of $182.55 billion, a PE ratio of 27.96, a price-to-earnings-growth ratio of 2.64 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $627.88. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company’s fifty day simple moving average is $441.06 and its two-hundred day simple moving average is $458.02.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company’s revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.95%.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 295 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $500.04, for a total transaction of $147,511.80. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $57,591,606.96. The trade was a 0.26% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 18,896 shares of company stock worth $8,593,838. Insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.